Maravai LifeSciences Holdings, Inc.
Maravai LifeSciences Holdings, Inc.
Your view on MRVI
Overview
What the company does, where it operates, and who runs it.
About Maravai LifeSciences Holdings, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Bernd Brust
- Headquarters
- 10770 Wateridge Circle, San Diego, CA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Bernd Brust
- Headquarters
- 10770 Wateridge Circle, San Diego, CA, US
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally.
The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.
It operates in two segments, Nucleic Acid Production and Biologics Safety Testing.
The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA).
This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology.
The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, and custom services.
The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. Maravai LifeSciences Holdings, Inc. was incorporated in 2020 and is headquartered in San Diego, California.
Stock Data
Price chart, volume, and trading data.
What moved it
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for Maravai LifeSciences Holdings, Inc. from FRC's valuation model, read against the market price. MRVI last traded at $7.54; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Maravai LifeSciences Holdings, Inc.. Starting points for Maravai LifeSciences Holdings, Inc.: EPS -$0.44, beta 0.62 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Maravai LifeSciences Holdings, Inc.. Maravai LifeSciences Holdings, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Maravai LifeSciences Holdings, Inc.. Trailing twelve-month EPS for Maravai LifeSciences Holdings, Inc. stands at -$0.44. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Current price
—
live quote
Analysts' target
$7.38
average of 4 firms, last 12 months
Analyst Ratings
- Strong Buy0
- Buy2
- Hold1
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | -$0.03 | -$0.01 | -$0.07 | -$0.08 |
| Low estimate | -$0.04 | -$0.01 | -$0.08 | -$0.17 |
| High estimate | -$0.03 | -$0.01 | -$0.06 | -$0.02 |
| No. of analysts | 5 | 2 | 5 | 5 |
| Year-ago EPS | -$0.04 | $0.011 | -$0.911 | — |
| Growth | +16.2% | — | — | — |
1Year-ago EPS includes one-time items; growth not shown.
Revenue Estimate
| Revenue | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $51.18M | $61.09M | $214.35M | $224.58M |
| Low estimate | $50.55M | $56.83M | $213.70M | $221.03M |
| High estimate | $51.84M | $65.36M | $215.00M | $228.37M |
| No. of analysts | 6 | 4 | 7 | 7 |
| Year-ago revenue | $49.87M | $65.84M | $185.74M | — |
| Growth | +2.6% | -7.2% | +15.4% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Benzinga; as of Nov 14, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Maravai LifeSciences Holdings, Inc.. Maravai LifeSciences Holdings, Inc. has reported as a listed company since 2020. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Peer companies
Market cap
- AZTAAzenta, Inc.Medical - Instruments & Supplies$2.0B
- BIOBio-Rad Laboratories, Inc.Medical - Devices$9.9B
- BLFSBioLife Solutions, Inc.Medical - Instruments & Supplies$1.9B
- LABStandard BioTools Inc.Medical - Specialties$279M
- NEOGNeogen CorporationMedical - Devices$2.5B
- PACBPacific Biosciences of California, Inc.Medical - Devices$609M
- RGENRepligen CorporationMedical - Instruments & Supplies$10.7B
- TECHBio-Techne CorporationBiotechnology$11.4B
More Biotechnology companies
- FNCHQFinch Therapeutics Group, Inc.OTC
- FORUForU Holdings, Inc.OTC$2,171
- FPMIFluoroPharma Medical, Inc.OTC$6,852
- FRNMFreenome, Inc. Common stockNASDAQ$85M
- FRX.TOFennec Pharmaceuticals Inc.TSX$581M
- FTHFaeth Therapeutics, Inc.NASDAQ$259M
- FTREFortrea Holdings Inc.NASDAQ$1.9B
- FULCFulcrum Therapeutics, Inc.NASDAQ$288M
- GALTGalectin Therapeutics Inc.NASDAQ$201M
- GANXGain Therapeutics, Inc.NASDAQ$44M
- GBIMGlobeImmune, Inc.OTC$575
- GBLXGB Sciences, Inc.OTC$122,121
ETFs holding Maravai LifeSciences Holdings, Inc.
% of the fund
- VTIVanguard Total Stock Market ETF$689.2B in assets0.00%
- IWMiShares Russell 2000 ETF$76.6B in assets0.03%
- VXFVanguard Extended Market ETF$30.2B in assets0.01%
- IWNiShares Russell 2000 Value ETF$13.9B in assets0.06%
- NIXTResearch Affiliates Deletions ETF$41M in assets0.89%
- GNOMGlobal X - Genomics & Biotechnology ETF$108M in assets0.62%
- FYXFirst Trust Small Cap Core AlphaDEX Fund$1.4B in assets0.25%
- FSCCFederated Hermes MDT Small Cap Core ETF$426M in assets0.17%
Largest holders first, then the funds most concentrated in MRVI.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Maravai LifeSciences Holdings, Inc., and how their positions are changing. At a $2.14B market value, institutional positions materially move Maravai LifeSciences Holdings, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Maravai LifeSciences Holdings, Inc. executives and directors. Shares of Maravai LifeSciences Holdings, Inc. have traded between $1.67 and $6.21 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
About this section
U.S. House of Representatives disclosures naming Maravai LifeSciences Holdings, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Maravai LifeSciences Holdings, Inc.. Coverage tracks Maravai LifeSciences Holdings, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Maravai LifeSciences Holdings, Inc.